IL300525A - תרכובות אזאציקלוהקסיל חומצה אצטית מותמרות בטריאזול–פירידיניל כאנטגוניסטים לקולטן lpa - Google Patents

תרכובות אזאציקלוהקסיל חומצה אצטית מותמרות בטריאזול–פירידיניל כאנטגוניסטים לקולטן lpa

Info

Publication number
IL300525A
IL300525A IL300525A IL30052523A IL300525A IL 300525 A IL300525 A IL 300525A IL 300525 A IL300525 A IL 300525A IL 30052523 A IL30052523 A IL 30052523A IL 300525 A IL300525 A IL 300525A
Authority
IL
Israel
Prior art keywords
compound
substituted
ring
methyl
occurrence
Prior art date
Application number
IL300525A
Other languages
English (en)
Original Assignee
Viva Star Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viva Star Biosciences Ltd filed Critical Viva Star Biosciences Ltd
Publication of IL300525A publication Critical patent/IL300525A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL300525A 2020-08-11 2021-10-09 תרכובות אזאציקלוהקסיל חומצה אצטית מותמרות בטריאזול–פירידיניל כאנטגוניסטים לקולטן lpa IL300525A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020108325 2020-08-11
PCT/IB2021/059266 WO2022034568A1 (en) 2020-08-11 2021-10-09 Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists

Publications (1)

Publication Number Publication Date
IL300525A true IL300525A (he) 2023-04-01

Family

ID=78179477

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300525A IL300525A (he) 2020-08-11 2021-10-09 תרכובות אזאציקלוהקסיל חומצה אצטית מותמרות בטריאזול–פירידיניל כאנטגוניסטים לקולטן lpa

Country Status (9)

Country Link
EP (1) EP4196220A1 (he)
JP (1) JP2023544476A (he)
KR (1) KR20240068583A (he)
CN (1) CN116669727A (he)
AU (1) AU2021323515A1 (he)
CA (1) CA3191452A1 (he)
IL (1) IL300525A (he)
MX (1) MX2023001812A (he)
WO (1) WO2022034568A1 (he)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
IL298082A (he) 2020-06-03 2023-01-01 Gilead Sciences Inc אנטגוניסטים של רצפטור lpa ושימושים בהם
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2022232459A1 (en) * 2021-04-30 2022-11-03 Viva Star Biosciences (Suzhou) Co., Ltd. Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists
KR20240005892A (ko) 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與lpa受體活性相關的病狀的化合物及組合物
WO2024022314A1 (zh) * 2022-07-25 2024-02-01 武汉人福创新药物研发中心有限公司 三氮唑类化合物及其作为lpar1拮抗剂的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1009690A2 (pt) * 2009-06-16 2015-08-25 Du Pont "célula hospedeira microbiana oleaginosa, óleo, método de elaboração de um óleo, método de aumento da eficiência de conversão de alongamento de c18 para c20 em uma célula hospedeira recombinante microbiana oleaginosa e método de aumento da eficiência de conversão de dessaturação (delta) 4 em uma célula hospedeira recombinante microbiana oleaginosa produtora de ácidos graxos póli-insaturados de cadeia longa"
WO2012100436A1 (en) * 2011-01-30 2012-08-02 Curegenix Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US9663513B2 (en) 2012-11-20 2017-05-30 Merck Sharp & Dohme Corp. Pyrimidine PDE10 inhibitors
US20140200215A1 (en) * 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
SG11201507459YA (en) * 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
US11261174B2 (en) * 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
CN112074515A (zh) * 2017-12-19 2020-12-11 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类

Also Published As

Publication number Publication date
WO2022034568A1 (en) 2022-02-17
JP2023544476A (ja) 2023-10-24
MX2023001812A (es) 2023-06-19
EP4196220A1 (en) 2023-06-21
KR20240068583A (ko) 2024-05-17
CA3191452A1 (en) 2022-02-17
AU2021323515A1 (en) 2023-03-09
CN116669727A (zh) 2023-08-29

Similar Documents

Publication Publication Date Title
IL300525A (he) תרכובות אזאציקלוהקסיל חומצה אצטית מותמרות בטריאזול–פירידיניל כאנטגוניסטים לקולטן lpa
KR101181194B1 (ko) 바이아릴 에터 우레아 화합물
AU2017304761C1 (en) Pharmaceutical compounds
BR112016011024B1 (pt) Composto, composição farmacêutica, e, usos dos mesmos
JP6378759B2 (ja) Sumo活性化酵素阻害剤として有用なヘテロアリール化合物
CA3085561A1 (en) Cyclohexyl acid triazole azines as lpa antagonists
EP2603500A1 (en) Inhibitors of bruton's tyrosine kinase
AU2009274027A1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
AU2017388376A1 (en) Poly-ADP ribose polymerase (PARP) inhibitors
CA3182873A1 (en) Sulphonamide compounds
AU2020421426A1 (en) RORγt inhibitor, preparation method thereof and use thereof
WO2023141570A2 (en) Compounds and methods for the targeted degradation of kras
CN112135818A (zh) 4-羟基哌啶衍生物及其作为泛素特异性蛋白酶19(usp19)的抑制剂的用途
WO2022232459A1 (en) Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists
WO2024026483A2 (en) Cdk2 inhibitors and methods of using the same
WO2024121779A1 (en) Papain-like protease (plpro) inhibitors
WO2023118253A1 (en) Cyclohexane acid derivatives as lpa receptor inhibitors
WO2023115149A1 (en) Bifunctional sulphonamide compounds
AU2022420983A1 (en) Bifunctional sulphonamide compounds
CN117659022A (zh) 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途
WO2023086521A1 (en) Btk inhibitors
WO2023004376A1 (en) Nitrile sumo inhibitors and uses thereof
TW202309039A (zh) 用於靶向布魯頓氏酪胺酸激酶降解之化合物
IL296602A (he) נגזרות n-(הטרוציקליל והטרוציקלילאלקיל)-3בנזילפירידין-2-אמין כאגונסטים של sstr4
KR20230083276A (ko) 오토탁신 억제제 화합물